Background: Convalescent plasma is a potential therapeutic option for critically ill patients with coronavirus disease 19 (COVID-19), yet its efficacy remains to be determined. The aim was to investigate the effects of convalescent plasma (CP) in critically ill patients with COVID-19.Methods: This was a single-center prospective observational study conducted in Rio de Janeiro, Brazil, from March 17th to May 30th, with final follow-up on June 30th. We included 113 laboratory-confirmed COVID-19 patients with respiratory failure. Primary outcomes were time to clinical improvement and survival within 28 days. Secondary outcomes included behavior of biomarkers and viral loads. Kaplan–Meier analyses and Cox proportional-hazards regression using propensity score with inverse-probability weighing were performed.Results: 41 patients received CP and 72 received standard of care (SOC). Median age was 61 years (IQR 48–68), disease duration was 10 days (IQR 6–13), and 86% were mechanically ventilated. At least 29 out of 41CP-recipients had baseline IgG titers ≥ 1:1,080. Clinical improvement within 28 days occurred in 19 (46%) CP-treated patients, as compared to 23 (32%) in the SOC group [adjusted hazard ratio (aHR) 0.91 (0.49–1.69)]. There was no significant change in 28-day mortality (CP 49% vs. SOC 56%; aHR 0.90 [0.52–1.57]). Biomarker assessment revealed reduced inflammatory activity and increased lymphocyte count after CP.Conclusions: In this study, CP was not associated with clinical improvement or increase in 28-day survival. However, our study may have been underpowered and included patients with high IgG titers and life-threatening disease.Clinical Trial Registration: The study protocol was retrospectively registered at the Brazilian Registry of Clinical Trials (ReBEC) with the identification RBR-4vm3yy (http://www.ensaiosclinicos.gov.br).

INTRODUCTION The novel coronavirus, called SARS-CoV-2, has as its main factor of the disease spreading the transmission between humans. COVID-19 is the name given by the World Health Organization (WHO) to identify the disease caused by this agent. Portugal is currently experiencing the pandemic Mitigation phase, in which, in addition to community transmission, it is assumed that there is local transmission in a closed environment. This disease was recognized by the WHO and by the Portugal Directorate-General of Health as Occupational Disease in a health care environment. OBJECTIVE Evaluate and characterize the presumed cases of occupational disease caused by SARS-CoV-2, among workers with COVID-19, considering the respective interpretation of the causal nexus, individually. METHODS Retrospective, descriptive, observational study (case-series), carried out between march and july 2020 in workers of a Portuguese oncology institute, dedicated to provide care for patients with cancer, reviewing files in the clinical processes of the occupational health service software (UTILSST®). It was considered the infection of workers with SARS-COV-2, as an inclusion criterion. RESULTS 41 workers were diagnosed with COVID-19, with an average age of 43.70 ± 11.63 years. Of these, 87.80% (n= 36) were female. The professional category with the highest infection rate in the institution was the auxiliaries of nursing [46.34%, n= 19], followed by nurses [39.02%, n = 16]. The most affected service was a Medical Oncology Service [31.4%, n= 11]. In the studied population, the prevalence of cases presumed to be Occupational Disease was 80.49% (n= 33). Of these, 48.5% (n= 16) were by direct contact with an infected patient, 30.3% (n = 10) without a known index case, but with a diagnosis obtained in “Disease mitigation phase” and 21.2% (n=7) by contact with an infected worker. In 19.51% (n= 8) of all the cases, no Occupational Disease was presumed, due to contact with an infected index case in a social/ family environment. CONCLUSION The main sources of nosocomial transmission with an assumed causal nexus are patients with COVID-19. It is essential to put into practice and ensure the maintenance of adequate collective and individual protection measures to combat this disease, as well as ensuring a permanent update of the institution’s infection control program so that the risk of exposure is controlled.

No abstract

N/a.

Engenharia -Educação. 2. Engenharia de produção. 3.Planejamento estratégico. I. Título. CDD 658.5 Elaborado por Maurício Amormino Júnior -CRB6/2422 O conteúdo dos artigos e seus dados em sua forma, correção e confiabilidade são de responsabilidade exclusiva dos autores. 2018 Permitido o download da obra e o compartilhamento desde que sejam atribuídos créditos aos autores, mas sem a possibilidade de alterá-la de nenhuma forma ou utilizá-la para fins comerciais.